EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab Exposure

Prerna Mewawalla, Rachel Dileo, Yue Yin, Christopher Strouse, Hira Shaikh, James A Davis, Omar Alkharabsheh, Aliya Rashid, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.06.015 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Prerna Mewawalla und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Antibodies, Bispecific. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaB-Cell Maturation AntigenAntibodies, BispecificHumansMiddle AgedMaleAgedFemaleAdultAged, 80 and overRetrospective StudiesTreatment OutcomeImmunotherapy, AdoptiveAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Antibody-drug conjugateBispecific antibodiesCAR-TExtramedullary diseaseHigh-risk cytogenetics

Substanzen

B-Cell Maturation Antigenbelantamab mafodotinAntibodies, BispecificAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA.
  • Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh, PA.
  • Division of Hematology, Oncology, and Blood and Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Hospital and Clinics, Iowa City, IA.
  • Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC.
  • University of South Alabama Mitchell Cancer Institute, Mobile, AL.
  • Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, MO.

Zitieren

APA

Mewawalla, P., Dileo, R., Yin, Y., Strouse, C., Shaikh, H., Davis, J. A., Alkharabsheh, O., Rashid, A., Ahmed, N., Abdallah, A. O., & Hashmi, H. (2025). Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab Exposure. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.06.015

Vancouver

Mewawalla P, Dileo R, Yin Y, Strouse C, Shaikh H, Davis JA, et al. Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab Exposure. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.06.015

BibTeX
@article{Mewawalla2025,
  author = {Mewawalla, Prerna and Dileo, Rachel and Yin, Yue and Strouse, Christopher and Shaikh, Hira and Davis, James A and Alkharabsheh, Omar and Rashid, Aliya and Ahmed, Nausheen and Abdallah, Al-Ola and Hashmi, Hamza},
  title = {Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab Exposure},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.06.015}
}
Kostenlos starten →